Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Prudential PLC

Prudential PLC cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 27.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 3,471 shares of the biopharmaceutical company’s stock after selling 1,322 shares during the quarter. Prudential PLC’s holdings in Regeneron Pharmaceuticals were worth $2,472,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of REGN. Norges Bank acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $802,036,000. Amundi lifted its position in shares of Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock valued at $1,138,074,000 after acquiring an additional 487,489 shares during the last quarter. Loomis Sayles & Co. L P lifted its position in shares of Regeneron Pharmaceuticals by 33.4% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock valued at $1,122,168,000 after acquiring an additional 393,997 shares during the last quarter. Proficio Capital Partners LLC boosted its stake in shares of Regeneron Pharmaceuticals by 92,865.3% during the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock worth $156,284,000 after acquiring an additional 219,162 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock worth $1,726,940,000 after acquiring an additional 155,369 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 6.1 %

Regeneron Pharmaceuticals stock opened at $573.45 on Monday. The company has a market capitalization of $62.69 billion, a P/E ratio of 14.98, a P/E/G ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a 1-year low of $536.30 and a 1-year high of $1,211.20. The firm’s fifty day simple moving average is $676.70 and its 200-day simple moving average is $776.59. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $11.86 earnings per share. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.61%. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Analyst Ratings Changes

REGN has been the subject of several analyst reports. Citigroup reduced their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. Sanford C. Bernstein cut their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. JPMorgan Chase & Co. reduced their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for the company in a research report on Monday, March 31st. Finally, UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $966.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.